The development of second-generation antidepressants, which have fewer side effects and help maintain therapy adherence, could be hindered by the IRA. These advancements are crucial for patients with major depressive disorders, as they reduce discontinuation rates due to side effects. Without these newer antidepressants, a significant portion of patients might stop their treatment, leading to worse outcomes and increased mental health challenges.
The analysis was commissioned by the Partnership to Fight Chronic Disease (PFCD) and conducted by Lumanity.
